by The human microbiome market is capitalizing on probiotics and prebiotics to harness the gut-brain axis and impact mental health. The global human microbiome industry plays a crucial role in understanding the role of microbes in various diseases and therapeutics development. Microbiome-based drugs and diagnostics help modulate gut bacteria composition for treating numerous conditions.
The human microbiome consists of trillions of microorganisms like bacteria, fungi, viruses, and protozoa that inhabit the human body. Microbiome products like probiotics and prebiotics support digestive health, boost immunity, and influence cognitive behavior via the bidirectional communication pathway between the gut and brain known as the gut–brain axis. Microbiota-targeted diagnostics and therapeutics showcase potential for neuropsychiatric disorders, metabolic diseases, and gastrointestinal ailments. Understanding host-microbe interactions aids developing microbiome-modifying drugs with fewer side effects than conventional medications.
Global Human Microbiome Market is estimated to be valued at US$ 4894.33 million in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024-2031
Key Takeaways
Key players operating in the human microbiome market are Diageo plc, Pernod-Ricard SA, Constellation Brands Inc., Brown-Forman Corporation, Remy Cointreau SA, Marie Brizard Wine & Spirits, Lapostolle SA, and Berentzen-Gruppe AG. Rising prevalence of lifestyle diseases and the influence of gut health on mental wellbeing are fueling interest in microbiome-oriented diagnostic tests and therapeutics. Growing consumer awareness about probiotic supplements and personalized nutrition is propelling the demand for microbiome-based products.
Market Key Trends:
The Human Microbiome Market Demand industry is witnessing increased research on psychobiotics and their effects on the brain-gut-microbiota axis. Psychobiotics comprise live organisms that produce a health benefit on mental state and nervous system function. Modulating gut microbial composition through specific strains of psychobiotics shows promise for mood, anxiety, depression, autism, and other neurodevelopmental and neurodegenerative conditions. Researchers are exploring novel psychobiotic formulations and their neurological impacts, offering lucrative opportunities for players in the human microbiome market.
Porter’s Analysis
Threat of new entrants: Low as the market is highly capital intensive due to research and development costs. Bargaining power of buyers: Moderate as there are few companies dominating the global market. Bargaining power of suppliers: Low as raw materials suppliers have less influence on the prices in this market. Threat of new substitutes: Low as there are limited substitutes for microbial therapies currently. Competitive rivalry: High as major players compete for market share and strive to develop new products.
Geographical Regions
North America accounts for the largest share of the human microbiome market currently valued at around 35% of the global market due to growing prevalence of lifestyle diseases and rising R&D spending.
Asia Pacific region is expected to witness the fastest growth during the forecast period supported by developing healthcare infrastructure, increasing healthcare spending, large patient pool suffering from various chronic diseases and rising awareness regarding microbiome-based therapeutics in the region.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
